Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

ATP-sensitive potassium channels are important for hair growth.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study found that TPA treatment transiently induces high levels of ODC in mouse epidermal cells, particularly around hair follicles, with localization reduced by retinoic acid or cycloheximide pretreatment.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.

This report describes a 60-year-old female with pretibial pruritic papular dermatitis who showed significant improvement of skin lesions after one month of treatment with oral pentoxifylline. The authors highlight the unique clinical and histological features of PPPD and propose pentoxifylline as a potential therapy.

This study reports that while DCP had similar treatment efficacy in propylene glycol and isopropanol for alopecia areata, the formulation in isopropanol was better tolerated.

This study found that PDCD4 protein expression is reduced in various skin cancers compared to normal skin, suggesting its potential role in preventing or treating certain skin cancers.

This study found that new methods for isolating human dermal papilla cells were more efficient than traditional methods, maintaining higher levels of specific markers and improving the cells' research potential.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that both new and old formulas of DCP for treating alopecia areata resulted in similar hair regrowth, but tolerance was significantly better with DCP in isopropanol.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

This study found that inhibiting the enzyme ornithine decarboxylase (ODC) prevented UVB-induced basal cell carcinomas in a mouse model, suggesting ODC is a potential target for chemoprevention strategies.

This study found that a single application of TCDD on the skin of hairless mice altered epidermal differentiation, changing keratin expression patterns similarly to a known tumor promoter.

This letter discusses three plasmacytoid dendritic cell-related parameters that may help differentiate lupus alopecia from lichen planopilaris, but it reports no new study results.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

In this study, overexpression of ornithine decarboxylase accelerated basal cell carcinoma in Ptch1+/– mice under UVB exposure, while its inhibition reduced tumor induction, suggesting potential chemoprevention strategies in humans.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.

In this study, deep phenotyping of 68 patients with XPD gene defects successfully separated individuals by clinical diagnosis and survival status, potentially improving diagnosis and prognosis for xeroderma pigmentosum and trichothiodystrophy.

A new method improves the isolation of hair follicle cells for better hair growth research.

This study established a rapid and accurate ultra-performance liquid chromatographic method for chemical fingerprinting and analyzing Platycladi cacumen, effectively distinguishing batches based on geographical and climatic conditions.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

This report describes two cases where patients developed vitiligo as a side effect of diphencyprone treatment for alopecia areata, highlighting the need to inform patients about this potential adverse effect.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.